Restoration of WNT4 inhibits cell growth in leukemia-derived cell lines

BMC Cancer

Beatriz García-Castro³  Monserrat Alvarez-Zavala³  Alma R Riveros-Magaña²  Pablo C Ortíz-Lazareno¹  Sarah Ratkovich-González¹  Georgina Hernández-Flores¹  Alejandro Bravo-Cuellar¹  Luis F Jave-Suarez¹  Adriana Aguilar-Lemarroy¹ 

[1] División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Sierra Mojada No. 800, Col. Independencia, 44340 Guadalajara, Jalisco, Mexico

[2] Programa de Doctorado en Investigación Clínica, CUCS - Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

[3] Programa de Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud (CUCS) - Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

关键词: FZD6;    Non-canonical pathway;    Hematopoietic malignancies;    Leukemia;    WNT signaling;    WNT4;   

Others  :  859241
DOI  :  10.1186/1471-2407-13-557

 received in 2013-02-05, accepted in 2013-11-22,  发布年份 2013

【 摘 要 】

Background

WNT signaling pathways are significantly altered during cancer development. Vertebrates possess two classes of WNT signaling pathways: the “canonical” WNT/β-catenin signaling pathway, and the “non-canonical” pathways including WNT/Ca2⁺ and WNT/Planar cell polarity [PCP] signaling. WNT4 influences hematopoietic progenitor cell expansion and survival; however, WNT4 function in cancer development and the resulting implications for oncogenesis are poorly understood.

The aim of this study was twofold: first, to determine the expression of WNT4 in mature peripheral blood cells and diverse leukemia-derived cells including cell lines from hematopoietic neoplasms and cells from patients with leukemia; second, to identify the effect of this ligand on the proliferation and apoptosis of the blast-derived cell lines BJAB, Jurkat, CEM, K562, and HL60.

Methods

We determined WNT4 expression by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) in peripheral blood mononuclear cells (PBMCs) and T- and B-lymphocytes from healthy individuals, as well as from five leukemia-derived cell lines and blasts derived from patients with leukemia. To analyze the effect of WNT4 on cell proliferation, PBMCs and cell lines were exposed to a commercially available WNT4 recombinant human protein. Furthermore, WNT4 expression was restored in BJAB cells using an inducible lentiviral expression system. Cell viability and proliferation were measured by the addition of WST-1 to cell cultures and counting cells; in addition, the progression of the cell cycle and the amount of apoptosis were analyzed in the absence or presence of WNT4. Finally, the expression of WNT-pathway target genes was measured by qRT-PCR.

Results

WNT4 expression was severely reduced in leukemia-derived cell lines and blasts derived from patients with leukemia. The exposure of cell lines to WNT4 recombinant protein significantly inhibited cell proliferation; inducing WNT4 expression in BJAB cells corroborated this observation. Interestingly, restoration of WNT4 expression in BJAB cells increased the accumulation of cells in G1 phase, and did not induce activation of canonical WNT/β-catenin target genes.

Conclusions

Our findings suggest that the WNT4 ligand plays a role in regulating the cell growth of leukemia-derived cells by arresting cells in the G1 cell cycle phase in an FZD6-independent manner, possibly through antagonizing the canonical WNT/β-catenin signaling pathway.

【 授权许可】

   
2013 García-Castro et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006, 5(12):997-1014.
• [2]Chien AJ, Moon RT: WNTS and WNT receptors as therapeutic tools and targets in human disease processes. Front Biosci 2007, 12:448-457.
• [3]Staal FJ, Sen JM: The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis. Eur J Immunol 2008, 38(7):1788-1794.
• [4]Nusse R: Wnt signaling. Cold Spring Harb Perspect Biol 2012., 4(5)
• [5]Gordon MD, Nusse R: Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006, 281(32):22429-22433.
• [6]Vincent JP, Beckett K: Off-track takes Frizzled off the canonical path. EMBO J 2011, 30(18):3665-3666.
• [7]Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature 2005, 434(7035):843-850.
• [8]Polakis P: Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012., 4(5)
• [9]Ge X, Wang X: Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol 2010, 3:33. BioMed Central Full Text
• [10]Khan NI, Bradstock KF, Bendall LJ: Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol 2007, 138(3):338-348.
• [11]Nygren MK, Dosen G, Hystad ME, Stubberud H, Funderud S, Rian E: Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines. Br J Haematol 2007, 136(3):400-413.
• [12]Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA: Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2004, 101(9):3118-3123.
• [13]Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A, Gerstein R, Jurecic R, Jones SN: Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 2003, 4(5):349-360.
• [14]Heinonen KM, Vanegas JR, Brochu S, Shan J, Vainio SJ, Perreault C: Wnt4 regulates thymic cellularity through the expansion of thymic epithelial cells and early thymic progenitors. Blood 2011, 118(19):5163-5173.
• [15]Heinonen KM, Vanegas JR, Lew D, Krosl J, Perreault C: Wnt4 enhances murine hematopoietic progenitor cell expansion through a planar cell polarity-like pathway. PLoS One 2011, 6(4):e19279.
• [16]Wan X, Ji W, Mei X, Zhou J, Liu JX, Fang C, Xiao W: Negative feedback regulation of Wnt4 signaling by EAF1 and EAF2/U19. PLoS One 2010, 5(2):e9118.
• [17]Lyons JP, Mueller UW, Ji H, Everett C, Fang X, Hsieh JC, Barth AM, McCrea PD: Wnt-4 activates the canonical beta-catenin-mediated Wnt pathway and binds Frizzled-6 CRD: functional implications of Wnt/beta-catenin activity in kidney epithelial cells. Exp Cell Res 2004, 298(2):369-387.
• [18]Bui TD, Zhang L, Rees MC, Bicknell R, Harris AL: Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma. Br J Cancer 1997, 75(8):1131-1136.
• [19]Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL: Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 1994, 54(10):2615-2621.
• [20]Bonifas JM, Pennypacker S, Chuang PT, McMahon AP, Williams M, Rosenthal A, De Sauvage FJ, Epstein EH Jr: Activation of expression of hedgehog target genes in basal cell carcinomas. J Invest Dermatol 2001, 116(5):739-742.
• [21]Sercan Z, Pehlivan M, Sercan HO: Expression profile of WNT, FZD and sFRP genes in human hematopoietic cells. Leuk Res 2010, 34(7):946-949.
• [22]Memarian A, Hojjat-Farsangi M, Asgarian-Omran H, Younesi V, Jeddi-Tehrani M, Sharifian RA, Khoshnoodi J, Razavi SM, Rabbani H, Shokri F: Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. Leuk Lymphoma 2009, 50(12):2061-2070.
• [23]Memarian A, Vosough P, Asgarian-Omran H, Tabrizi M, Shabani M, Shokri F: Differential WNT Gene Expression in Various Subtypes of Acute Lymphoblastic Leukemia. Iran J Immunol 2012, 9(1):61-71.
• [24]Niehrs C, Acebron SP: Mitotic and mitogenic Wnt signalling. EMBO J 2012, 31(12):2705-2713.
• [25]Zimmerman ZF, Moon RT, Chien AJ: Targeting wnt pathways in disease. Cold Spring Harb Perspect Biol 2012., 4(11)
• [26]Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S, Nagayama M: Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer Sci 2003, 94(7):593-597.
• [27]De Menna M, D’Amato V, Ferraro A, Fusco A, Di Lauro R, Garbi C, De Vita G: Wnt4 inhibits cell motility induced by oncogenic Ras. Oncogene 2013, 32(35):4110-9.
• [28]Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, Hammond M, Van Scoyk M, Acosta H, Mirus J, Barry N, et al.: Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem 2005, 280(20):19625-19634.
• [29]Winn RA, Van Scoyk M, Hammond M, Rodriguez K, Crossno JT Jr, Heasley LE, Nemenoff RA: Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 2006, 281(37):26943-26950.
• [30]Spinsanti P, De Vita T, Caruso A, Melchiorri D, Misasi R, Caricasole A, Nicoletti F: Differential activation of the calcium/protein kinase C and the canonical beta-catenin pathway by Wnt1 and Wnt7a produces opposite effects on cell proliferation in PC12 cells. J Neurochem 2008, 104(6):1588-1598.
• [31]Ochoa-Hernandez AB, Ramos-Solano M, Meza-Canales ID, Garcia-Castro B, Rosales-Reynoso MA, Rosales-Avina JA, Barrera-Chairez E, Ortiz-Lazareno PC, Hernandez-Flores G, Bravo-Cuellar A, et al.: Peripheral T-lymphocytes express WNT7A and its restoration in leukemia-derived lymphoblasts inhibits cell proliferation. BMC Cancer 2012, 12:60. BioMed Central Full Text
• [32]Ripka S, Konig A, Buchholz M, Wagner M, Sipos B, Kloppel G, Downward J, Gress T, Michl P: WNT5A–target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 2007, 28(6):1178-1187.
• [33]Li Q, Kannan A, Das A, Demayo FJ, Hornsby PJ, Young SL, Taylor RN, Bagchi MK, Bagchi IC: WNT4 Acts Downstream of BMP2 and Functions via beta-Catenin Signaling Pathway to Regulate Human Endometrial Stromal Cell Differentiation. Endocrinology 2013, 154(1):446-57.
• [34]Heller C, Kuhn MC, Mulders-Opgenoorth B, Schott M, Willenberg HS, Scherbaum WA, Schinner S: Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic beta-cell proliferation. Am J Physiol Endocrinol Metab 2011, 301(5):E864-E872.
• [35]Miyakoshi T, Takei M, Kajiya H, Egashira N, Takekoshi S, Teramoto A, Osamura RY: Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway. Endocr Pathol 2008, 19(4):261-273.
• [36]Bernard P, Fleming A, Lacombe A, Harley VR, Vilain E: Wnt4 inhibits beta-catenin/TCF signalling by redirecting beta-catenin to the cell membrane. Biol Cell 2008, 100(3):167-177.
• [37]van Amerongen R, Nusse R: Towards an integrated view of Wnt signaling in development. Development 2009, 136(19):3205-3214.
• [38]Peradziryi H, Kaplan NA, Podleschny M, Liu X, Wehner P, Borchers A, Tolwinski NS: PTK7/Otk interacts with Wnts and inhibits canonical Wnt signalling. EMBO J 2011, 30(18):3729-3740.
• [39]Tokuhara M, Hirai M, Atomi Y, Terada M, Katoh M: Molecular cloning of human Frizzled-6. Biochem Biophys Res Commun 1998, 243(2):622-627.
• [40]Terra R, Louis I, Le Blanc R, Ouellet S, Zuniga-Pflucker JC, Perreault C: T-cell generation by lymph node resident progenitor cells. Blood 2005, 106(1):193-200.